Ieq Capital LLC Acquires New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Ieq Capital LLC bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 20,502 shares of the biotechnology company’s stock, valued at approximately $352,000.

A number of other institutional investors have also modified their holdings of the stock. Creative Planning boosted its holdings in shares of ADMA Biologics by 52.0% in the third quarter. Creative Planning now owns 54,947 shares of the biotechnology company’s stock valued at $1,098,000 after purchasing an additional 18,800 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in ADMA Biologics by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 1,509 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of ADMA Biologics in the 3rd quarter worth $2,658,000. New York State Teachers Retirement System bought a new position in shares of ADMA Biologics during the 3rd quarter worth $1,821,000. Finally, SteelPeak Wealth LLC purchased a new position in shares of ADMA Biologics during the third quarter valued at $471,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Trading Down 2.2 %

Shares of NASDAQ ADMA opened at $15.44 on Friday. ADMA Biologics, Inc. has a 1-year low of $5.08 and a 1-year high of $23.64. The business has a fifty day moving average price of $16.80 and a 200 day moving average price of $18.00. The stock has a market capitalization of $3.65 billion, a P/E ratio of 55.14 and a beta of 0.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ADMA shares. HC Wainwright upped their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.